Niraparib + Abiraterone Acetate + Prednisone for Prostate Cancer

(HARMONY Trial)

No longer recruiting at 1 trial location

Overseen By Ahran Lee

Age: 18+

Sex: Male

Trial Phase: Phase 2

Sponsor: Qian Qin

Must not be taking: Second generation ARIs, Chemotherapy

Disqualifiers: Neuroendocrine features, Brain metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of medications—niraparib, abiraterone acetate, and prednisone—to treat men with metastatic hormone-sensitive prostate cancer. It focuses on patients whose cancer has specific genetic changes affecting DNA repair, such as BRCA mutations. Participants must have a confirmed diagnosis of prostate cancer that has spread but hasn't been heavily treated. The trial aims to determine if this combination can manage cancer more effectively in patients with these genetic profiles. As a Phase 2 trial, researchers focus on measuring the treatment's effectiveness in an initial, smaller group of people.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop your current medications, but it does allow short-term use of corticosteroids and requires that long-term use of certain corticosteroids be avoided. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the combination of niraparib, abiraterone acetate, and prednisone has been tested for safety in treating prostate cancer. Many patients tolerated this combination well, though some experienced side effects. Common side effects included fatigue, nausea, and low blood cell counts. These effects are typical for treatments that impact hormone levels and the body's DNA repair ability.

Importantly, this combination has shown promise in helping patients with certain genetic changes, such as BRCA mutations. While side effects can occur, they are often manageable. Overall, the safety profile suggests it is generally well-tolerated, but individual experiences may vary. It is important to consult a healthcare provider about potential risks when considering joining a clinical trial. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about the combination of niraparib, abiraterone acetate, and prednisone for prostate cancer because it offers a novel multi-targeted approach. Unlike standard treatments like androgen deprivation therapy (ADT) alone, this combination includes niraparib, a PARP inhibitor, which targets DNA repair mechanisms in cancer cells, potentially making the treatment more effective against resistant cancer types. Additionally, the dual action tablet (DAT) combines niraparib and abiraterone acetate, simplifying the treatment regimen and enhancing patient compliance. This innovative strategy aims to improve outcomes by tackling cancer from multiple fronts simultaneously.

What evidence suggests that this trial's treatments could be effective for prostate cancer?

In this trial, participants will receive a combination of niraparib, abiraterone acetate, and prednisone to treat prostate cancer. Research has shown that this combination may be effective for prostate cancer with certain genetic changes. Studies indicate that it can reduce the risk of cancer progression by 56% in patients with specific gene mutations, such as BRCA. Additionally, there is a trend suggesting that this treatment may extend patient survival compared to standard care. While researchers continue to collect more survival data, early results appear promising. This treatment targets genetic weaknesses in the cancer, potentially halting its growth. ^{1 3 6 7 8}

Who Is on the Research Team?

Qian Qin, MD

Principal Investigator

UT Southwestern Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for men aged 18+ with newly diagnosed metastatic hormone-sensitive prostate cancer and specific genetic alterations (like BRCA1/2, PALB2). Participants must have minimal prior treatment, adequate organ function, and an ECOG Performance Status of ≤ 2. It's open to Hispanic/Latino or non-Hispanic black individuals.

Inclusion Criteria

I have signed the consent form and agreed to share my health information.

I identify as Hispanic/Latino or non-Hispanic black.

My prostate cancer was confirmed through a tissue examination.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Treatment

Participants receive ADT with a GnRH agonist or antagonist, 200 mg niraparib, 1,000 mg abiraterone acetate, and 5 mg prednisone daily for 24 weeks (6 cycles) unless there is progression or unacceptable toxicity.

24 weeks

Cohort B Treatment Extension

Participants with PSA ≤ 4 ng/mL without progression continue ADT + niraparib/abiraterone acetate plus prednisone for 1 year unless progression or unacceptable toxicity.

1 year

Cohort A Treatment Extension

Participants with PSA > 4 ng/mL without progression have the option to continue ADT + niraparib/abiraterone acetate plus prednisone for 2 years or switch to ADT, abiraterone acetate plus prednisone, and docetaxel for 6 doses.

2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment completion.

4 years

What Are the Treatments Tested in This Trial?

Interventions

• Abiraterone Acetate
• Niraparib
• Prednisone

Trial Overview The study tests Niraparib combined with Abiraterone Acetate and Prednisone in patients who haven't had extensive previous treatments. The goal is to see how well this combination works on prostate cancer with certain genetic changes related to DNA repair.

How Is the Trial Designed?

Group I: Initial Treatment (Cycle 1 to Cycle 6) Experimental Treatment 3 Interventions

Androgen Deprivation Therapy (ADT) with a GnRH agonist or antagonist per standard of care. 200 mg niraparib and 1,000 mg abiraterone acetate dual action tablet (DAT, Akeega) once daily, with 5mg prednisone once daily for 24 weeks (6 cycles) unless there is progression or unacceptable toxicity. After 6 cycles, disease evaluation performed.

Group II: Cohort B: PSA ≤ 4 ng/mL without progression at the completion of 24 weeks Experimental Treatment 3 Interventions

Continue ADT + niraparib/abiraterone acetate plus prednisone for 1 year unless progression or unacceptable toxicity. At 1 year, disease evaluation will occur. * PSA ≥ 0.2 ng/mL: ADT + niraparib/abiraterone acetate plus prednisone will continue for 2 years or until progression or unacceptable toxicity. Therapy beyond 2 years will be per standard of care per investigator discretion. * PSA \< 0.2 ng/mL and PSA not trending up: 1. Continue ADT + niraparib/abiraterone acetate plus prednisone for 2 years or until progression or unacceptable toxicity. Therapy beyond 2 years will be per standard of care per investigator discretion OR 2. STOP ADT + niraparib/abiraterone acetate plus prednisone only IF: * C14 PSA \< 0.2 AND not trending up * Subjects not eligible that elect to stop ADT + niraparib/abiraterone acetate plus prednisone, will be removed from protocol treatment and move to follow-up. Subsequent therapy re-initiation will be at the discretion per standard of care.

Group III: Cohort A: prostate specific antigen (PSA) >4 ng/mL without progression at the completion of 24 weeks Experimental Treatment 5 Interventions

After 6 cycles, there will be an option to: 1. Continue ADT + niraparib/abiraterone acetate plus prednisone in 28-day cycles for a total of 2 years OR until disease progression or unacceptable toxicity. Subsequent therapy will be at the discretion of the investigator per standard of care. 2. Discontinue niraparib. Continue ADT, start abiraterone acetate plus prednisone and docetaxel 75mg/m2 in 21-day cycles. Docetaxel every 3 weeks x 6 doses. At the completion of docetaxel, the subject will move to follow-up per protocol. Niraparib should not be restarted at the completion of docetaxel. Subsequent therapy will be at the discretion of the investigator per standard of care.

Who Is Running the Clinical Trial?

Qian Qin

Lead Sponsor

Trials

2

Recruited

130+

UT Southwestern Comprehensive Cancer Center

Collaborator

Trials

1

Recruited

60+

Janssen, LP

Industry Sponsor

Trials

169

Recruited

329,000+

Founded

1953

Headquarters

Beerse, Belgium

Known For

Mental Health Therapies

Top Products

Imodium, Remicade, Invega, Procrit

Joaquin Duato

Janssen, LP

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD

Janssen, LP

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University

Published Research Related to This Trial

In a phase III trial involving men with metastatic castration-resistant prostate cancer (mCRPC), abiraterone acetate combined with prednisone significantly improved overall survival and radiographic progression-free survival compared to placebo.

The incidence of corticosteroid-related adverse events was similar between the treatment and placebo groups, indicating that while monitoring for side effects is necessary, the benefits of improved survival with abiraterone acetate plus prednisone outweigh the risks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. Crawford, ED., Shore, ND., Petrylak, DP., et al.[2020]

In a study of 131 patients with high-risk, nonmetastatic, castration-resistant prostate cancer, treatment with abiraterone acetate and prednisone resulted in an impressive 86.9% of patients achieving a 50% or greater reduction in prostate-specific antigen (PSA) levels, indicating strong efficacy.

The treatment also showed promising secondary outcomes, with a median time to PSA progression of 28.7 months, while safety was generally acceptable, although 96.2% of patients experienced adverse events, highlighting the need for careful monitoring.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. Ryan, CJ., Crawford, ED., Shore, ND., et al.[2021]

In a phase 3 trial involving 1199 patients, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly improved overall survival, with a median survival not reached in the abiraterone group compared to 34.7 months in the placebo group.

The study also showed that patients receiving abiraterone had a median radiographic progression-free survival of 33.0 months, compared to 14.8 months in the placebo group, indicating a strong benefit in delaying disease progression.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi, K., Tran, N., Fein, L., et al.[2022]

In a clinical trial involving 164 men with metastatic castration-resistant prostate cancer, abiraterone acetate combined with prednisone (5 mg twice daily) or dexamethasone (0.5 mg once daily) effectively minimized mineralocorticoid excess, which is important for patient safety.

While abiraterone with dexamethasone showed promising efficacy, it was also linked to adverse metabolic effects, such as increased insulin resistance and decreased bone mineral density, highlighting the need for careful monitoring of these side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. Attard, G., Merseburger, AS., Arlt, W., et al.[2022]

In a phase 3 trial with 1088 patients, abiraterone acetate plus prednisone significantly improved overall survival compared to placebo plus prednisone, with a median survival of 34.7 months versus 30.3 months, indicating its efficacy in treating chemotherapy-naive castration-resistant prostate cancer.

The treatment was associated with a manageable safety profile, although there were some increased risks of grade 3-4 adverse events, such as cardiac disorders and elevated liver enzymes, suggesting that while effective, monitoring for side effects is important.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Ryan, CJ., Smith, MR., Fizazi, K., et al.[2022]

Niraparib (NIRA) is an effective treatment for patients with metastatic castration-resistant prostate cancer who have specific genetic alterations, showing promising results in a Phase II study.

When combined with abiraterone acetate and prednisone, NIRA demonstrated a manageable safety profile while effectively disrupting cancer cell signaling pathways.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. Chi, KN., Fleshner, N., Chiuri, VE., et al.[2023]

In a study of 133 patients with non-metastatic castration-resistant prostate cancer, abiraterone acetate (AA) plus prednisone showed comparable overall survival and cancer-specific survival to enzalutamide (Enz) over a median follow-up of 36 months.

However, patients treated with AA plus prednisone had a significantly higher risk of non-cancer-caused death compared to those treated with Enz, suggesting that while both treatments are effective, AA plus prednisone may pose additional safety concerns.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer. Tsujino, T., Tokushige, S., Komura, K., et al.[2023]

In a study of 104 patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate, the median overall survival was 16.4 months, highlighting the drug's effectiveness in this patient population.

Key prognostic factors for overall survival included early PSA response (greater than 30% decline at four weeks) and ECOG performance status, suggesting that these metrics can help identify patients who are more likely to benefit from abiraterone acetate treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. España, S., Ochoa de Olza, M., Sala, N., et al.[2022]

Abiraterone acetate (AA) combined with prednisone shows favorable safety and efficacy outcomes in treating metastatic prostate cancer, particularly in patients who are asymptomatic or have mild symptoms.

The treatment is generally well tolerated, but it is important to be aware of its known toxicity profile, including mineralocorticoid and corticosteroid-related adverse events, as well as hepatotoxicity, which can inform clinical decision-making.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. Castellan, P., Castellucci, R., Marchioni, M., et al.[2019]

In a study of 148 patients with metastatic castration-resistant prostate cancer, maintaining abiraterone acetate plus prednisone (AAP) during docetaxel treatment did not improve radiographic progression-free survival compared to docetaxel plus prednisone alone, with rates of 34.9% and 33.9% respectively after 12 months.

The combination of docetaxel and AAP resulted in significantly higher rates of severe neutropenia (59.6%) compared to docetaxel plus prednisone (27.7%), suggesting that continuing AAP may increase treatment-related risks without providing additional benefits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. Climent, MA., Font, A., Durán, I., et al.[2022]

Niraparib at a dose of 200 mg/day was determined to be the recommended phase 2 dose when combined with abiraterone acetate plus prednisone (AAP) for patients with metastatic castration-resistant prostate cancer (mCRPC), as it showed a tolerable safety profile with no new safety signals.

The combination of niraparib with apalutamide resulted in a higher incidence of dose-limiting toxicities, leading to the decision not to further evaluate this combination, highlighting the importance of monitoring drug interactions in treatment regimens.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Saad, F., Chi, KN., Shore, ND., et al.[2021]

In the IPATential150 trial involving 1097 patients with metastatic castration-resistant prostate cancer, adding ipatasertib to abiraterone and prednisone significantly improved radiographic progression-free survival for patients with PTEN-loss tumors.

While ipatasertib was associated with a higher rate of serious adverse events and treatment discontinuation compared to placebo, its overall safety profile was considered tolerable, suggesting that with proper management, the side effects could be mitigated.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Matsubara, N., de Bono, J., Sweeney, C., et al.[2023]

In a phase II study involving 41 men with metastatic castration-resistant prostate cancer, increasing the dose of abiraterone acetate from 1000 mg to 2000 mg daily did not result in any significant clinical benefit, as no patients showed a prostate-specific antigen (PSA) decline of 30% or more after 12 weeks.

The study found that factors such as lower baseline circulating androgen levels and individual differences in drug metabolism may contribute to resistance against standard-dose abiraterone therapy, suggesting that simply increasing the dose is not an effective strategy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Friedlander, TW., Graff, JN., Zejnullahu, K., et al.[2018]

Citations

1. nature.com nature.com/articles/s41591-025-03961-8

Niraparib and abiraterone acetate plus prednisone for ... The data for overall survival, a key secondary endpoint, are immature (193/389 events) but favor niraparib (hazard ratio = 0.79 (95% confidence ...

2. ncbi.nlm.nih.gov ncbi.nlm.nih.gov/books/NBK604453/

Clinical Review - Niraparib and Abiraterone Acetate (Akeega) Even though the expected 5-year survival for males diagnosed with prostate cancer in Canada is 91% for all stages combined, when the disease progresses to the ...

3. urotoday.com urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/161080-asco-2025-phase-3-amplitude-trial-niraparib-and-abiraterone-acetate-plus-prednisone-for-metastatic-castration-sensitive-prostate-cancer-patients-with-alterations-in-homologous-recombination-repair-genes.html

ASCO 2025: Phase 3 AMPLITUDE Trial: Niraparib and ... Dr. Attard highlighted that the combination of niraparib and AAP significantly reduced the risk of symptomatic progression by 56% in the BRCAm ...

4. euoncology.europeanurology.com euoncology.europeanurology.com/article/S2588-9311(25)00107-5/fulltext

Niraparib and Abiraterone Acetate plus Prednisone in ... The MAGNITUDE final analysis showed a trend towards better overall survival with niraparib + abiraterone acetate and prednisone (AAP) versus ...

5. jnj.com jnj.com/innovativemedicine/emea/newsroom/johnson-johnsons-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-is-the-first-parp-inhibitor-combo-to-show-improved-efficacy-in-patients-with-hrr-mutated-mhspc-vs-current-standard-of-care

Johnson & Johnson's AKEEGA® (niraparib and ... Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening ...

6. clinicaltrials.gov clinicaltrials.gov/study/NCT04497844

NCT04497844 | A Study of Niraparib in Combination With ... The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone

7. sciencedirect.com sciencedirect.com/science/article/pii/S2588931125001075

Niraparib and Abiraterone Acetate plus Prednisone in ... The MAGNITUDE final analysis showed a trend towards better overall survival with niraparib + abiraterone acetate and prednisone (AAP) versus placebo + AAP.

8. jnj.com jnj.com/media-center/press-releases/janssen-presents-updated-data-demonstrating-improved-outcomes-from-the-use-of-niraparib-in-combination-with-abiraterone-acetate-plus-prednisone-as-a-first-line-therapy-in-patients-with-brca-positive-metastatic-castration-resistant-prostate-cancer

Janssen Presents Updated Data Demonstrating Improved ... Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone ...